ABP-110

N/A

Report date: 2026/03/19 17:01:34

Base Information

Drug NameABP-110

Drug Alias NameABP-110

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionImmunostimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-Glypican-3 +[5]

TargetsGlypican-3T cell surface glycoprotein CD3

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Institutes Of Health Abpro Corp

China Registration ClassN/A

Develop Information

Active CompaniesAbpro Corp

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A